Brind.

Adaptive Biotechnologies and Genentech have terminated their strategic collaboration agreement.

2 reports, 2 independent Updated Aug 25

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Adaptive Biotechnologies and Genentech have terminated their strategic collaboration agreement.

Who's involved

What this event is mainly about

Hoffmann-La Roche Adaptive Biotechnologies

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
Adaptive Biotechnologies
company in Seattle, United States
- Adaptive Biotechnologies presented findings at the IMS meeting in Glasgow on September 25, 2026.Fri 14:06

Coverage

Newest first; wire copies grouped

Aug 25Insider MonkeyAdaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the must-buy small-cap stocks to invest in. On Au
Aug 24Simply Wall St.Adaptive Biotechnologies (ADPT): Evaluating Valuation Following Genentech Collaboration Wind-Down and Strategic Refocus If you are following Adaptive Biotechnologies (ADPT), the news that its collabo